CHICAGO (GenomeWeb) – Two next-generation precision oncology drugs, one an EGFR inhibitor and an ALK inhibitor, have shown to be far more effective against advanced non-small cell lung cancer than older drugs in their class.
At the American Society of Clinical Oncology's annual meeting, researchers presented data from two head-to-head NSCLC trials, one comparing the first targeted EGFR inhibitor Iressa (gefitinib) against the next-generation dacomitinib; and another comparing the first ALK-inhibitor Xalkori (crizotinib) against newer agent Alecensa (alectinib).